Antibody-Mediated PD-L1 to PD-1 Binding for Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive agents are ineffective in addressing autoimmune diseases, allergic diseases, and graft-versus-host diseases by promoting the binding of PD-L1 to PD-1.
Innovation Solution
Development of an immunosuppressive agent containing an anti-CD80 antibody or an anti-PD-L1 antibody that promotes the binding of PD-L1 to PD-1, thereby inhibiting immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-L1 antibody is used to inhibit CD80/PD-L1 interaction, then tumor immunity is activated, but the physiological function of CD80/PD-L1 interaction is not elucidated and off-target effects may occur
Solution Approach 1:
The patent applies local quality by designing an antibody that specifically targets the CD80/PD-L1 interaction interface with high precision. The antibody's binding site is localized to the specific region where CD80 and PD-L1 interact, allowing selective disruption of this interaction without affecting other immune pathways. This localized targeting reduces off-target effects while maintaining specific immunosuppressive activity.
Solution Approach 2:
The patent uses an antibody as an intermediary substance that mediates the disruption of CD80/PD-L1 interaction. The antibody binds to either CD80 or PD-L1, acting as a bridge that prevents the direct interaction between these two molecules. This intermediary approach allows controlled modulation of the specific interaction while avoiding direct toxicity to either target molecule.
2Productivity
If CD80/PD-L1 interaction is inhibited to activate tumor immunity, then cancer treatment efficacy improves, but the mechanism is not fully understood and may cause unexpected immune responses
Solution Approach 1:
The patent incorporates feedback mechanisms by monitoring the interaction between CD80 and PD-L1 in real-time. The antibody design includes features that allow detection of the interaction state, providing feedback on whether the antibody is effectively blocking the interaction. This feedback loop enables optimization of the antibody's binding affinity and specificity to ensure consistent immunosuppressive activity without unexpected immune responses.
Solution Approach 2:
The patent applies parameter changes by modifying the binding characteristics of the antibody to CD80 or PD-L1. Through optimization of the antibody's affinity, valency, and binding kinetics, the patent achieves precise control over the disruption of CD80/PD-L1 interaction. These parameter adjustments allow the antibody to effectively block the interaction while maintaining safety and predictability of the immune modulation effect.
3Adaptability or versatility
If existing immunosuppressive agents are used, then general immunosuppression is achieved, but they are ineffective for specific diseases like autoimmune, allergic, and graft-versus-host diseases
Solution Approach 1:
The patent applies segmentation by dividing the immune system's regulatory mechanisms into specific, targetable components. Instead of using broad, non-specific immunosuppressants, the patent targets the specific CD80/PD-L1 interaction pathway that is dysregulated in autoimmune, allergic, and graft-versus-host diseases. This segmented approach allows disease-specific immunosuppression by interfering with the particular molecular interaction that drives pathology in each condition.
Solution Approach 2:
The patent achieves universality through a single antibody mechanism that can address multiple disease types. The CD80/PD-L1 interaction is implicated in various immune-mediated conditions including autoimmune diseases, allergic reactions, and graft-versus-host disease. By targeting this conserved interaction pathway, the patent creates a multi-functional immunosuppressive agent that can be applied across different disease indications, providing both specificity and versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunosuppressive agent effectively suppresses immune responses, providing prophylactic and therapeutic benefits for autoimmune diseases, allergic diseases, and graft-versus-host diseases.
Implementation Method 1
a substance that promotes the binding of PD-L1 to PD-1 and is selected from an anti-CD80 antibody and an anti-PD-L1 antibody
Data Source
AI summary
The present application provides an immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.